Provided by Tiger Trade Technology Pte. Ltd.

Galapagos NV

32.48
+0.12000.37%
Post-market: 32.480.00000.00%17:39 EST
Volume:114.60K
Turnover:3.74M
Market Cap:2.14B
PE:-4.18
High:32.92
Open:32.54
Low:32.45
Close:32.36
52wk High:37.78
52wk Low:22.36
Shares:65.90M
Float Shares:65.05M
Volume Ratio:1.04
T/O Rate:0.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.7644
EPS(LYR):1.16
ROE:-16.72%
ROA:-5.19%
PB:0.74
PE(LYR):27.91

Loading ...

Galapagos to Look At Strategic Alternatives After Drug Doesn't Meet Trial Goal

Dow Jones
·
Dec 19

Galapagos Reports Topline Data From Two Trials With GLPG3667 in Dermatomyositis, Systemic Lupus Erythematosus

MT Newswires Live
·
Dec 19

Galapagos NV Receives Transparency Notifications from Bank of America

TIPRANKS
·
Nov 26

RBC Adjusts Price Target on Galapagos to $32 From $28, Maintains Sector Perform Rating

MT Newswires Live
·
Nov 08

Galapagos NV expected to post a loss of 41 cents a share - Earnings Preview

Reuters
·
Nov 03

Galapagos NV Strengthens Board with Strategic Appointments

TIPRANKS
·
Oct 31

RBC Raises Price Target on Galapagos to $28 From $27, Keeps Sector Perform Rating

MT Newswires Live
·
Oct 22

Galapagos Nv : Leerink Partners Raises to Outperform From Market Perform; Raises Target Price to $40 From $29

THOMSON REUTERS
·
Oct 22

Galapagos (GLPG) Gets a Hold from RBC Capital

TIPRANKS
·
Oct 22

Galapagos Raised to Outperform From Market Perform by Leerink Partners

Dow Jones
·
Oct 22

Leerink upgrades Galapagos on confidence after cell therapy exit

TIPRANKS
·
Oct 22

Top Premarket Decliners

MT Newswires Live
·
Oct 21

Galapagos Shares Sink on Plans to Wind Down Cell-Therapy Business

Dow Jones
·
Oct 21

Galapagos intends to wind down cell therapy business

TIPRANKS
·
Oct 21

Analysts Offer Insights on Healthcare Companies: Galapagos (GLPG), Pharvaris (PHVS) and Stevanato Group (STVN)

TIPRANKS
·
Oct 13

Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Stevanato Group (STVN) and Galapagos (GLPG)

TIPRANKS
·
Oct 06

Galapagos Exploring Divesting From Cell Therapy Business

Dow Jones
·
Oct 02

Galapagos provides update on strategic alternatives for cell therapy business

TIPRANKS
·
Oct 02

Morgan Stanley Sticks to Its Sell Rating for Galapagos (GLPG)

TIPRANKS
·
Sep 15

Galapagos Nv : Leerink Partners Raises Target Price to $29 From $24

THOMSON REUTERS
·
Jul 24